Drugs / PfSPZ Challenge
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02115516 | Apr 2014 → Dec 2015 | Plasmodium falciparum malaria | Sanaria Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03952650 | May 2019 → Feb 2021 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03503058 | May 2022 → Feb 2024 | malaria | Sanaria Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PfSPZ Challenge | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03503058 ↗ |
| Modality | Vaccine | “PfSPZ Challenge is a malaria vaccine.” NCT03952650 ↗ |
| Route | Intravenous | “PfSPZ Challenge administered IV” NCT02115516 ↗ |